BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 15531454)

  • 41. MicroRNA expression, chromosomal alterations, and immunoglobulin variable heavy chain hypermutations in Mantle cell lymphomas.
    Navarro A; Beà S; Fernández V; Prieto M; Salaverria I; Jares P; Hartmann E; Mozos A; López-Guillermo A; Villamor N; Colomer D; Puig X; Ott G; Solé F; Serrano S; Rosenwald A; Campo E; Hernández L
    Cancer Res; 2009 Sep; 69(17):7071-8. PubMed ID: 19690137
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
    Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
    Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bendamustine is effective in p53-deficient B-cell neoplasms and requires oxidative stress and caspase-independent signaling.
    Roué G; López-Guerra M; Milpied P; Pérez-Galán P; Villamor N; Montserrat E; Campo E; Colomer D
    Clin Cancer Res; 2008 Nov; 14(21):6907-15. PubMed ID: 18980985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Shiraishi T; Yoshida T; Nakata S; Horinaka M; Wakada M; Mizutani Y; Miki T; Sakai T
    Cancer Res; 2005 Jul; 65(14):6364-70. PubMed ID: 16024639
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nuclear and cytoplasmic death receptor 5 as prognostic factors in patients with non-small cell lung cancer treated with chemotherapy.
    Leithner K; Stacher E; Wurm R; Ploner F; Quehenberger F; Wohlkoenig C; Bálint Z; Polachova J; Olschewski A; Samonigg H; Popper HH; Olschewski H
    Lung Cancer; 2009 Jul; 65(1):98-104. PubMed ID: 19081160
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A single nucleotide polymorphism in the extracellular domain of TRAIL receptor DR4 at nucleotide 626 in gastric cancer patients in Japan.
    Kuraoka K; Matsumura S; Sanada Y; Nakachi K; Imai K; Eguchi H; Matsusaki K; Oue N; Nakayama H; Yasui W
    Oncol Rep; 2005 Aug; 14(2):465-70. PubMed ID: 16012731
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Quantitative microsatellite analysis to delineate the commonly deleted region 1p22.3 in mantle cell lymphomas.
    Balakrishnan A; von Neuhoff N; Rudolph C; Kamphues K; Schraders M; Groenen P; van Krieken JH; Callet-Bauchu E; Schlegelberger B; Steinemann D
    Genes Chromosomes Cancer; 2006 Oct; 45(10):883-92. PubMed ID: 16830336
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of death receptor 4 haplotype 626C-683C with an increased breast cancer risk.
    Frank B; Hemminki K; Shanmugam KS; Meindl A; Klaes R; Schmutzler RK; Wappenschmidt B; Untch M; Bugert P; Bartram CR; Burwinkel B
    Carcinogenesis; 2005 Nov; 26(11):1975-7. PubMed ID: 15975957
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumor necrosis factor-related apoptosis-inducing ligand-mediated proliferation of tumor cells with receptor-proximal apoptosis defects.
    Baader E; Toloczko A; Fuchs U; Schmid I; Beltinger C; Ehrhardt H; Debatin KM; Jeremias I
    Cancer Res; 2005 Sep; 65(17):7888-95. PubMed ID: 16140959
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin.
    Yoshida T; Shiraishi T; Horinaka M; Wakada M; Sakai T
    Oncol Rep; 2007 Nov; 18(5):1239-42. PubMed ID: 17914579
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways.
    Fernàndez V; Hartmann E; Ott G; Campo E; Rosenwald A
    J Clin Oncol; 2005 Sep; 23(26):6364-9. PubMed ID: 16155021
    [TBL] [Abstract][Full Text] [Related]  

  • 52. TNF-alpha-related apoptosis-inducing ligand decoy receptor DcR2 is targeted by androgen action in the rat ventral prostate.
    Vindrieux D; Réveiller M; Florin A; Blanchard C; Ruffion A; Devonec M; Benahmed M; Grataroli R
    J Cell Physiol; 2006 Mar; 206(3):709-17. PubMed ID: 16245307
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The utility of interphase fluorescence in situ hybridization for the detection of the translocation t(11;14)(q13;q32) in the diagnosis of mantle cell lymphoma on fine-needle aspiration specimens.
    Caraway NP; Gu J; Lin P; Romaguera JE; Glassman A; Katz R
    Cancer; 2005 Apr; 105(2):110-8. PubMed ID: 15712276
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies.
    Inoue S; MacFarlane M; Harper N; Wheat LM; Dyer MJ; Cohen GM
    Cell Death Differ; 2004 Dec; 11 Suppl 2():S193-206. PubMed ID: 15608694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Transcription factor NF-kappaB differentially regulates death receptor 5 expression involving histone deacetylase 1.
    Shetty S; Graham BA; Brown JG; Hu X; Vegh-Yarema N; Harding G; Paul JT; Gibson SB
    Mol Cell Biol; 2005 Jul; 25(13):5404-16. PubMed ID: 15964798
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation.
    Jung EM; Park JW; Choi KS; Park JW; Lee HI; Lee KS; Kwon TK
    Carcinogenesis; 2006 Oct; 27(10):2008-17. PubMed ID: 16613838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Acquired potential N-glycosylation sites within the tumor-specific immunoglobulin heavy chains of B-cell malignancies.
    Zabalegui N; de Cerio AL; Inogés S; Rodríguez-Calvillo M; Pérez-Calvo J; Hernández M; García-Foncillas J; Martín-Algarra S; Rocha E; Bendandi M
    Haematologica; 2004 May; 89(5):541-6. PubMed ID: 15136216
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genomic instability at the human CD5 gene promoter.
    López-de la Iglesia A; Calvo J; Sanz-Vaqué L; Colomer D; Places L; García-Foncillas J; Campo E; Vives J; Lozano F
    Haematologica; 2002 Mar; 87(3):235-41. PubMed ID: 11869933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. TRAIL death receptor-4 expression positively correlates with the tumor grade in breast cancer patients with invasive ductal carcinoma.
    Sanlioglu AD; Korcum AF; Pestereli E; Erdogan G; Karaveli S; Savas B; Griffith TS; Sanlioglu S
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(3):716-23. PubMed ID: 17512128
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mechanisms of resistance to TRAIL-induced apoptosis in cancer.
    Zhang L; Fang B
    Cancer Gene Ther; 2005 Mar; 12(3):228-37. PubMed ID: 15550937
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.